Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Sells 1,000 Shares of Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) CFO Benjamin Hohl sold 1,000 shares of the firm’s stock in a transaction dated Friday, May 3rd. The shares were sold at an average price of $22.50, for a total transaction of $22,500.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.

Benjamin Hohl also recently made the following trade(s):

• On Monday, April 29th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total transaction of $55,152.50.
• On Thursday, April 11th, Benjamin Hohl sold 14,000 shares of Enliven Therapeutics stock. The shares were sold at an average price of $24.72, for a total transaction of $346,080.00.
• On Wednesday, March 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $18.25, for a total transaction of $59,312.50.
• On Tuesday, February 27th, Benjamin Hohl sold 3,250 shares of Enliven Therapeutics stock. The stock was sold at an average price of $16.97, for a total value of $55,152.50.

Enliven Therapeutics Stock Up 7.8 %

NASDAQ ELVN traded up $1.78 during trading on Tuesday, hitting $24.70. The company’s stock had a trading volume of 608,889 shares, compared to its average volume of 244,340. Enliven Therapeutics, Inc. has a 52 week low of $9.80 and a 52 week high of $26.00. The firm has a market cap of $1.16 billion, a P/E ratio of -11.19 and a beta of 1.05. The firm has a 50 day moving average price of $17.53 and a 200 day moving average price of $14.80.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.56) by $0.09. On average, equities analysts expect that Enliven Therapeutics, Inc. will post -2.16 earnings per share for the current year.

Hedge Funds Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. boosted its position in Enliven Therapeutics by 67.0% in the first quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after buying an additional 3,189 shares in the last quarter. AJOVista LLC bought a new stake in Enliven Therapeutics during the 4th quarter worth approximately $28,000. Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 9.1% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock valued at $170,000 after purchasing an additional 1,029 shares during the last quarter. SG Americas Securities LLC boosted its stake in Enliven Therapeutics by 17.8% in the fourth quarter. SG Americas Securities LLC now owns 13,501 shares of the company’s stock worth $187,000 after purchasing an additional 2,041 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its holdings in shares of Enliven Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after purchasing an additional 2,208 shares during the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Mizuho started coverage on shares of Enliven Therapeutics in a research report on Tuesday, April 9th. They set a “buy” rating and a $34.00 target price for the company.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.